View Author
patient response imatinib myeloid leukemia treatment cytarabine leukemia myeloid study posaconazole cytogenetic response level cytogenetic netherland analysis prophylaxi combination survival phase blood therapy combination therapy month result fluconazole hematologic cycle table blast expression center trial uncertainty infection death probability value blast crisis toxicity fl uconazole hematologic response model disease university progression bcr-abl azole resistance crisis 1 year indo expression indoleamine dioxygenase itraconazole scenario 800 mg group incidence uconazole range antifungal outcome estimate 12 months grade intermediate-dose cytarabine protocol number evaluation high-dose efficacy prophylactic follow-up life expectancy azole prophylaxis response rate dose level department methylation figure
8 Most Recent Publications
|
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group
(Article)
Thielen, N. Holt, B. van der Schipperus, M.R. Schattenberg, A.V.M.B. Marwijk Kooy, R. van Smit, W.M. Chu, I.W.T. Valk, P.J.M. Ossenkoppele, G.J. Cornelissen, J.J. Verhoef, G.E.G. Ammerlaan, R.A.H.M. Sonneveld, P. Janssen, J.J.W.M. Deenik, W. Falkenburg, J.H.F. Kersten, M.J. Sinnige, H. |
2013-04-10
|
|
Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib
(Article)
Deenik, W. Holt, B. van der Janssen, J.J.W.M. Chu, I.W.T. Valk, P.J.M. Ossenkoppele, G.J. Heiden, I.P. van der Sonneveld, P. Schaik, R.H.N. van Cornelissen, J.J. |
2010-12-23
|
|
Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands
(Article)
Jansen, J.P. O'Sullivan, A.K. Lugtenburg, P.J. Span, L.F.R. Janssen, J.J.W.M. Stam, W.B. |
2010-09-01
|
|
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia
(Article)
Deenik, W. Janssen, J.J.W.M. Sonneveld, P. Marwijk Kooy, M. van Wittebol, S. Willemze, R. Wijermans, P.W. Beverloo, H.B. Löwenberg, B. Valk, P.J.M. Ossenkoppele, G.J. Cornelissen, J.J. Holt, B. van der Verhoef, G.E.G. Smit, W.M. Kersten, M.J. Daenen, S.M.G.J. Verdonck, L.F. Ferrant, A. Schattenberg, A.V.M.B. |
2010-06-01
|
|
Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells
(Article)
Janssen, J.J.W.M. Denkers, F. Valk, P.J.M. Cornelissen, J.J. Schuurhuis, G.J. Ossenkoppele, G.J. |
2010-06-01
|
|
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome
(Article)
Chamuleau, M.E.D. Loosdrecht, A.A. van de Hess, C.J. Janssen, J.J.W.M. Zevenbergen, A. Delwel, H.R. Valk, P.J.M. Löwenberg, B. Ossenkoppele, G.J. |
2008-12-01
|
|
Economic evaluation of posaconazole vs. standard azole prophylaxis in high risk neutropenic patients in the Netherlands
(Article)
Stam, W.B. O'Sullivan, A.K. Rijnders, B.J.A. Lugtenburg, P.J. Span, L.F.R. Janssen, J.J.W.M. Jansen, J.P. |
2008-12-01
|
|
Dose-finding study of imatinib in combination with intravenous cytarabine: Feasibility in newly diagnosed patients with chronic myeloid leukemia
(Article)
Deenik, W. Holt, B.D. van Sonneveld, P. Kooy, M.M. van Wittebol, S. Willemze, R. Wijermans, P.W. Westveer, P.H.M. Beverloo, H.B. Valk, P.J.M. Löwenberg, B. Ossenkoppele, G.J. Verhoef, G.E.G. Cornelissen, J.J. Smit, W.M. Kersten, M.J. Kluin-Nelemans, H.C. Verdonck, L.F. Ferrant, A. Schattenberg, A.V.M.B. Janssen, J.J.W.M. |
2008-03-01
|
